CAMBRIDGE, MA, March 13, 2017 -- Aurora BioPharma, a clinical stage biotechnology company, developing genetically programmed CAR T Cell Therapy to treat Liquid and Solid tumors, will attend the 29th Annual ROTH Conference on March 13, 2017 at the Ritz Carlton, Laguna Niguel, in Dana Point, CA. Robert Brooks, President and CEO, will be available for one-on-one meetings.
The ROTH conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with close to 500 participating companies and over 4,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including: Healthcare, Technology, Internet & Media, Cleantech, Industrial Growth & Solar, Consumer, Oil & Gas, Mining & Minerals and Business Services.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, with an extensive clinical pipeline. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after radical amputation of a limb and chemotherapy, survival is poor. A completed Phase I/IIa trial in 19 Sarcoma (16 Osteosarcoma) patients was completed, Aurora's CAR T agent AU-101 met its endpoints of safety, with strong signs of tumor killing efficacy, and long term survivors.
Glioblastoma is the most common and deadliest form of brain cancer. Aurora's CAR T agent AU105 showed in a completed Phase I/IIa clinical trial in 16 Glioblastoma patients, safety, tumor killing efficacy, and double the median historic overall survival. Aurora is planning a randomized multi-site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma.
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.